1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 1,267 results.

$Thumbnail for Long-term follow-up of pediatric/young adult patients with relapsed/refractory KMT2Ar acute leukemia treated with revumenib in AUGMENT-101$

AML - 623

Long-term follow-up of pediatric/young adult patients with relapsed/refractory KMT2Ar acute leukemia treated with revumenib in AUGMENT-101

Branko Cuglievan

Poster Presenter: Branko Cuglievan

Thumbnail for GLP-1 Receptor Agonist Exposure and Survival Outcomes in Newly Diagnosed Multiple Myeloma Treated With Daratumumab-Based Quadruplet Therapy: A Target Trial Emulation

MM - 626

GLP-1 Receptor Agonist Exposure and Survival Outcomes in Newly Diagnosed Multiple Myeloma Treated With Daratumumab-Based Quadruplet Therapy: A Target Trial Emulation

Colton Jones

Poster Presenter: Colton Jones

SOHO 2026 Annual Meeting

Topics

Long-term follow-up of pediatric/young adult patients with relapsed/refractory KMT2Ar acute leukemia treated with revumenib in AUGMENT-101

GLP-1 Receptor Agonist Exposure and Survival Outcomes in Newly Diagnosed Multiple Myeloma Treated With Daratumumab-Based Quadruplet Therapy: A Target Trial Emulation

KIT Mutation-Driven Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia: Superior Outcomes With Intensive Chemotherapy in Newly Diagnosed Patients

A Multicenter, Phase 1 Study of KITE-753 in Patients With Relapsed/Refractory (R/R) B-Cell Lymphoma (BCL): Updated Safety and Efficacy Results

Frequency and Factors Predisposing to Pulmonary Infections in Patients With Chronic Lymphocytic Leukemia Treated With Targeted Agents

Revumenib Therapy Post-Hematopoietic Stem Cell Transplant for Patients With Relapsed/Refractory KMT2Ar, NPM1m, and NUP98r Acute Myeloid Leukemia: Post Hoc Analysis of Outcomes From AUGMENT-101

Treatment of high-risk smoldering multiple myeloma (HRSMM) with Isatuximab, lenalidomide, oral Cyclophosphamide and Dexamethasone: a survival advantage

Treatment of higher risk Myelodysplastic Syndrome HR-MDS with high-dose chemotherapy followed by lenalidomide and azacitidine: a four-year survival update

Ruxolitinib-Induced Complete Molecular Remission in Polycythemia Vera